ERBB3 and neoplasm: Patients with tumours positive for both EGFR and HER3 had similar outcome than patients EGFR FISH+/HER3− (OR=36.4 vs 29.4%, P=1.0; DCR=63.6 vs 58.8%, P=1.0; TTP=7.7 vs 9.0 months, P=0.32, and OS=13.8 vs 18.7 months, P=0.85).